Evidence map›Paper›PMID 37873106›Full record

ArticlebioRxiv : the preprint server for biology2023

G6PD Maintains Redox Homeostasis and Biosynthesis in LKB1-Deficient KRAS-Driven Lung Cancer.

Taijin Lan, Sara Arastu, Samuel Wang, Jarrick Lam, Wenping Wang, Vrushank Bhatt, Eduardo Cararo Lopes, Zhixian Hu, Michael Sun, Xuefei Luo and 6 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Taijin LanRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA.
Sara ArastuRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA.
Samuel WangRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA.
Jarrick LamRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA.
Wenping WangRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA.
Vrushank BhattRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA.
Eduardo Cararo LopesRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA.
Zhixian HuRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA.
Michael SunRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA.
Xuefei LuoRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA.
Jonathan M GhergurovichDepartment of Molecular Biology, Princeton University, Princeton, New Jersey 08544, USA.
Changlong LiWest China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu 610041, China.
Xiaoyang SuRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA.
Joshua D RabinowitzDepartment of Chemistry, Princeton University, Princeton, New Jersey 08544, USA.
Eileen WhiteRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA.
Jessie Yanxiang GuoRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA.
Rutgers, The State University of New Jersey · USPrinceton University · USWest China Medical Center of Sichuan University · CN

Funding

TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5M
Tumor cell metabolism in actionR01CA163591 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI JOSHUA D RABINOWITZ, Eileen P. White · 2012 to 2026
$7.0M
Elucidate the mechanism of autophagy in supporting Lkb1-deficient lung tumorigenesis and metastasisR01CA237347 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI GUO, YANXIANG · 2020 to 2025
$1.8M
Targeting autophagy to increase the sensitivity of LKB1-deficient lung tumors to angiogenesis inhibitorR21CA263136 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI GUO, YANXIANG · 2022 to 2023
$400k
NCI NIH HHS P30 CA072720NCI NIH HHS R01 CA163591NCI NIH HHS R01 CA237347NCI NIH HHS R21 CA263136
6 · The paper itself

Abstract

Cancer cells depend on nicotinamide adenine dinucleotide phosphate (NADPH) to combat oxidative stress and support reductive biosynthesis. One major NAPDH production route is the oxidative pentose phosphate pathway (committed step: glucose-6-phosphate dehydrogenase, G6PD). Alternatives exist and can compensate in some tumors. Here, using genetically-engineered lung cancer model, we show that ablation of G6PD significantly suppresses

Indexed as

fatty acid synthesisG6PDKRASLKB1metabolic reprogrammingNADPHNSCLCRedoxserine metabolism

Identifiers

PMID37873106
PMCPMC10592603
OpenAlexW4387500046

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.